Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
